Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies

F. Pommeret; J. Colomba; C. Bigenwald; A. Laparra; S. Bockel; A. Bayle; J. M. Michot; T. Hueso; L. Albiges; P. Tiberghien; S. Marot; A. Jary; K. Lacombe; F. Barlesi; F. Griscelli; E. Colomba

doi:10.1016/j.annonc.2021.07.015

Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies

F. Pommeret, J. Colomba, C. Bigenwald, A. Laparra, S. Bockel, A. Bayle, J. M. Michot, T. Hueso, L. Albiges, P. Tiberghien, S. Marot, A. Jary, K. Lacombe, F. Barlesi, F. Griscelli, E. Colomba

Research output: Contribution to journal › Letter › peer-review

23 Citations (Scopus)

Original language	English
Pages (from-to)	1445-1447
Number of pages	3
Journal	Annals of Oncology
Volume	32
Issue number	11
DOIs	https://doi.org/10.1016/j.annonc.2021.07.015
Publication status	Published - 1 Nov 2021

Access to Document

10.1016/j.annonc.2021.07.015

Cite this

Pommeret, F., Colomba, J., Bigenwald, C., Laparra, A., Bockel, S., Bayle, A., Michot, J. M., Hueso, T., Albiges, L., Tiberghien, P., Marot, S., Jary, A., Lacombe, K., Barlesi, F., Griscelli, F., & Colomba, E. (2021). Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies. Annals of Oncology, 32(11), 1445-1447. https://doi.org/10.1016/j.annonc.2021.07.015

@article{f598ae3287f84947ac4e862a2d09b250,

title = "Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies",

author = "F. Pommeret and J. Colomba and C. Bigenwald and A. Laparra and S. Bockel and A. Bayle and Michot, {J. M.} and T. Hueso and L. Albiges and P. Tiberghien and S. Marot and A. Jary and K. Lacombe and F. Barlesi and F. Griscelli and E. Colomba",

note = "Funding Information: None declared. AB is a Principal/sub-Investigator of Clinical Trials for Abbvie, Adaptimmune, Adlai Nortye USA Inc, Aduro Biotech, Agios Pharmaceuticals, Amgen, Argen-X Bvba, Astex Pharmaceuticals, Astra Zeneca Ab, Aveo, Basilea Pharmaceutica International Ltd, Bayer Healthcare Ag, Bbb Technologies Bv, Beigene, BicycleTx Ltd, Blueprint Medicines, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol Myers Squibb, Ca, Celgene Corporation, Chugai Pharmaceutical Co, Clovis Oncology, Cullinan-Apollo, Curevac, Daiichi Sankyo, Debiopharm, Eisai, Eisai Limited, Eli Lilly, Exelixis, Faron Pharmaceuticals Ltd, Forma Tharapeutics, Gamamabs, Genentech, Glaxosmithkline, H3 Biomedicine, Hoffmann La Roche Ag, Imcheck Therapeutics, Innate Pharma, Institut De Recherche Pierre Fabre, Iris Servier, Iteos Belgium SA, Janssen Cilag, Janssen Research Foundation, Kura Oncology, Kyowa Kirin Pharm. Dev, Lilly France, Loxo Oncology, Lytix Biopharma As, Medimmune, Menarini Ricerche, Merck Sharp & Dohme Chibret, Merrimack Pharmaceuticals, Merus, Millennium Pharmaceuticals, Molecular Partners Ag, Nanobiotix, Nektar Therapeutics, Novartis Pharma, Octimet Oncology Nv, Oncoethix, Oncopeptides, Orion Pharma, Ose Pharma, Pfizer, Pharma Mar, Pierre Fabre, Medicament, Roche, Sanofi Aventis, Seattle Genetics, Sotio A.S, Syros Pharmaceuticals, Taiho Pharma, Tesaro, Turning Point Therapeutics, Xencor, received Research Grants from Astrazeneca, BMS, Boehringer Ingelheim, GSK, INCA, Janssen Cilag, Merck, Novartis, Pfizer, Roche, Sanofi, and Non-financial support (drug supplied) from Astrazeneca, Bayer, BMS, Boringher Ingelheim, GSK, Medimmune, Merck, NH TherAGuiX, Pfizer, Roche. JMM LA Pfizer, Novartis, Merck, Astra Zeneca, MSD, Roche, Ipsen, Bristol Myer Squibb, Astellas, Exeliquis, Amgen, Peloton therapeutics, Corvus Pharmaceuticals, all outside the submitted work. JMM is a principal/sub-investigator of clinical trials for Abbvie, Agios, Amgen, Astex, AstraZeneca, BMS, Boeringer Ingelheim, Celgene, Debiopharm, Forma, Genentech, GSK, Incyte, Innate Pharma, Janssen, Lilly, Loxo, Medimmune, MSD, Novartis, Pfizer, Pharmamar, Roche, Sanofi and Xencor; and reports non-financial support (drugs, equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.) from AstraZeneca, Roche, Novartis, Gilead, Celgene and Bristol-Myers Squibb, all outside the submitted work. LA received grants and honoraria from Pfizer, Novartis, BMS, Ipsen, Roche, AstraZeneca, Amgen, Astellas, Exelixis, Corvus Pharmaceuticals, Peloton therapeutics, MSD, and Merck, outside the submitted work. KL received Advisory boards, travels grants, educational activities from Gilead, MSD, Abbvie, ViiV Healthcare, all outside the submitted work. PT is employed by Etablissement Fran{\c c}ais du Sang, the French transfusion public service in charge of collecting and issuing blood components in France. FB has personal financial interests in AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Eli Lilly Oncology, F Hoffmann-La Roche, Novartis, Merck, MSD, Pierre Fabre, Pfizer, and Takeda; and institutional financial interests in AbbVie, ACEA, Amgen, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Eisai, Eli Lilly Oncology, F. Hoffmann-La Roche, Genentech, Ipsen, Ignyta, Innate Pharma, Loxo, Novartis, Medimmune, Merck, MSD, Pierre Fabre, Pfizer, Sanofi-Aventis, and Takeda. FB is an advisory board member for Amgen, Bayer, BMS, CheckMab, Celgene, Daiichi Sankyo, Incyte, Merck, Novartis, F. Hoffmann-La Roche, and Seattle Genetics, all outside the submitted work. EC has acted as a consultant and participated in advisory boards for Ipsen, BMS, Sanofi, and Tesaro and Clovis, all outside the submitted work. All other authors have declared no conflicts of interest.",

year = "2021",

month = nov,

day = "1",

doi = "10.1016/j.annonc.2021.07.015",

language = "English",

volume = "32",

pages = "1445--1447",

journal = "Annals of Oncology",

issn = "0923-7534",

number = "11",

}

Pommeret, F, Colomba, J, Bigenwald, C, Laparra, A, Bockel, S, Bayle, A, Michot, JM, Hueso, T, Albiges, L, Tiberghien, P, Marot, S, Jary, A, Lacombe, K, Barlesi, F, Griscelli, F & Colomba, E 2021, 'Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies', Annals of Oncology, vol. 32, no. 11, pp. 1445-1447. https://doi.org/10.1016/j.annonc.2021.07.015

TY - JOUR

T1 - Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies

AU - Pommeret, F.

AU - Colomba, J.

AU - Bigenwald, C.

AU - Laparra, A.

AU - Bockel, S.

AU - Bayle, A.

AU - Michot, J. M.

AU - Hueso, T.

AU - Albiges, L.

AU - Tiberghien, P.

AU - Marot, S.

AU - Jary, A.

AU - Lacombe, K.

AU - Barlesi, F.

AU - Griscelli, F.

AU - Colomba, E.

N1 - Funding Information: None declared. AB is a Principal/sub-Investigator of Clinical Trials for Abbvie, Adaptimmune, Adlai Nortye USA Inc, Aduro Biotech, Agios Pharmaceuticals, Amgen, Argen-X Bvba, Astex Pharmaceuticals, Astra Zeneca Ab, Aveo, Basilea Pharmaceutica International Ltd, Bayer Healthcare Ag, Bbb Technologies Bv, Beigene, BicycleTx Ltd, Blueprint Medicines, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol Myers Squibb, Ca, Celgene Corporation, Chugai Pharmaceutical Co, Clovis Oncology, Cullinan-Apollo, Curevac, Daiichi Sankyo, Debiopharm, Eisai, Eisai Limited, Eli Lilly, Exelixis, Faron Pharmaceuticals Ltd, Forma Tharapeutics, Gamamabs, Genentech, Glaxosmithkline, H3 Biomedicine, Hoffmann La Roche Ag, Imcheck Therapeutics, Innate Pharma, Institut De Recherche Pierre Fabre, Iris Servier, Iteos Belgium SA, Janssen Cilag, Janssen Research Foundation, Kura Oncology, Kyowa Kirin Pharm. Dev, Lilly France, Loxo Oncology, Lytix Biopharma As, Medimmune, Menarini Ricerche, Merck Sharp & Dohme Chibret, Merrimack Pharmaceuticals, Merus, Millennium Pharmaceuticals, Molecular Partners Ag, Nanobiotix, Nektar Therapeutics, Novartis Pharma, Octimet Oncology Nv, Oncoethix, Oncopeptides, Orion Pharma, Ose Pharma, Pfizer, Pharma Mar, Pierre Fabre, Medicament, Roche, Sanofi Aventis, Seattle Genetics, Sotio A.S, Syros Pharmaceuticals, Taiho Pharma, Tesaro, Turning Point Therapeutics, Xencor, received Research Grants from Astrazeneca, BMS, Boehringer Ingelheim, GSK, INCA, Janssen Cilag, Merck, Novartis, Pfizer, Roche, Sanofi, and Non-financial support (drug supplied) from Astrazeneca, Bayer, BMS, Boringher Ingelheim, GSK, Medimmune, Merck, NH TherAGuiX, Pfizer, Roche. JMM LA Pfizer, Novartis, Merck, Astra Zeneca, MSD, Roche, Ipsen, Bristol Myer Squibb, Astellas, Exeliquis, Amgen, Peloton therapeutics, Corvus Pharmaceuticals, all outside the submitted work. JMM is a principal/sub-investigator of clinical trials for Abbvie, Agios, Amgen, Astex, AstraZeneca, BMS, Boeringer Ingelheim, Celgene, Debiopharm, Forma, Genentech, GSK, Incyte, Innate Pharma, Janssen, Lilly, Loxo, Medimmune, MSD, Novartis, Pfizer, Pharmamar, Roche, Sanofi and Xencor; and reports non-financial support (drugs, equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.) from AstraZeneca, Roche, Novartis, Gilead, Celgene and Bristol-Myers Squibb, all outside the submitted work. LA received grants and honoraria from Pfizer, Novartis, BMS, Ipsen, Roche, AstraZeneca, Amgen, Astellas, Exelixis, Corvus Pharmaceuticals, Peloton therapeutics, MSD, and Merck, outside the submitted work. KL received Advisory boards, travels grants, educational activities from Gilead, MSD, Abbvie, ViiV Healthcare, all outside the submitted work. PT is employed by Etablissement Français du Sang, the French transfusion public service in charge of collecting and issuing blood components in France. FB has personal financial interests in AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Eli Lilly Oncology, F Hoffmann-La Roche, Novartis, Merck, MSD, Pierre Fabre, Pfizer, and Takeda; and institutional financial interests in AbbVie, ACEA, Amgen, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Eisai, Eli Lilly Oncology, F. Hoffmann-La Roche, Genentech, Ipsen, Ignyta, Innate Pharma, Loxo, Novartis, Medimmune, Merck, MSD, Pierre Fabre, Pfizer, Sanofi-Aventis, and Takeda. FB is an advisory board member for Amgen, Bayer, BMS, CheckMab, Celgene, Daiichi Sankyo, Incyte, Merck, Novartis, F. Hoffmann-La Roche, and Seattle Genetics, all outside the submitted work. EC has acted as a consultant and participated in advisory boards for Ipsen, BMS, Sanofi, and Tesaro and Clovis, all outside the submitted work. All other authors have declared no conflicts of interest.

PY - 2021/11/1

Y1 - 2021/11/1

UR - http://www.scopus.com/inward/record.url?scp=85114918583&partnerID=8YFLogxK

U2 - 10.1016/j.annonc.2021.07.015

DO - 10.1016/j.annonc.2021.07.015

M3 - Letter

C2 - 34352377

AN - SCOPUS:85114918583

SN - 0923-7534

VL - 32

SP - 1445

EP - 1447

JO - Annals of Oncology

JF - Annals of Oncology

IS - 11

ER -

Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies

Access to Document

Other files and links

Cite this